Global Liposomes Drug Delivery Market Growth 2025-2031

Publication ID:

LPI01250089

Publication Date:

January 17, 2025

Pages:

113

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Liposomes Drug Delivery market size is predicted to grow from US$ 3942 million in 2025 to US$ 7127 million in 2031; it is expected to grow at a CAGR of 10.4% from 2025 to 2031.
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
North America dominated the market with market share of 44% due to the high medical level. Following North America, Europe is the second largest market with market share of 36%. Asian Pacific regions are the third largest market with developed countries like Japan and many developing countries like China. Its market share is about 12%.
Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma and Sigma-Tau Group are the top 6 players of Liposomes Drug Delivery, with about 77% market shares.
The 鈥淟iposomes Drug Delivery Industry Forecast鈥� looks at past sales and reviews total world Liposomes Drug Delivery sales in 2024, providing a comprehensive analysis by region and market sector of projected Liposomes Drug Delivery sales for 2025 through 2031. With Liposomes Drug Delivery sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomes Drug Delivery industry.
This Insight Report provides a comprehensive analysis of the global Liposomes Drug Delivery landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposomes Drug Delivery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Liposomes Drug Delivery market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomes Drug Delivery and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomes Drug Delivery.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomes Drug Delivery market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segmentation by Application:
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Spectrum Pharmaceuticals
Shanghai New Asia
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposomes Drug Delivery market?
What factors are driving Liposomes Drug Delivery market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposomes Drug Delivery market opportunities vary by end market size?
How does Liposomes Drug Delivery break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposomes Drug Delivery Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Liposomes Drug Delivery by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Liposomes Drug Delivery by Country/Region, 2020, 2024 & 2031
2.2 Liposomes Drug Delivery Segment by Type
2.2.1 Liposomal Doxorubicin
2.2.2 Liposomal Amphoteracin B
2.2.3 Liposomal Paclitaxel
2.2.4 Others
2.3 Liposomes Drug Delivery Sales by Type
2.3.1 Global Liposomes Drug Delivery Sales Market Share by Type (2020-2025)
2.3.2 Global Liposomes Drug Delivery Revenue and Market Share by Type (2020-2025)
2.3.3 Global Liposomes Drug Delivery Sale Price by Type (2020-2025)
2.4 Liposomes Drug Delivery Segment by Application
2.4.1 Fungal Infection Therapy
2.4.2 Cancer & Tumor Therapy
2.4.3 Others
2.5 Liposomes Drug Delivery Sales by Application
2.5.1 Global Liposomes Drug Delivery Sale Market Share by Application (2020-2025)
2.5.2 Global Liposomes Drug Delivery Revenue and Market Share by Application (2020-2025)
2.5.3 Global Liposomes Drug Delivery Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Liposomes Drug Delivery Breakdown Data by Company
3.1.1 Global Liposomes Drug Delivery Annual Sales by Company (2020-2025)
3.1.2 Global Liposomes Drug Delivery Sales Market Share by Company (2020-2025)
3.2 Global Liposomes Drug Delivery Annual Revenue by Company (2020-2025)
3.2.1 Global Liposomes Drug Delivery Revenue by Company (2020-2025)
3.2.2 Global Liposomes Drug Delivery Revenue Market Share by Company (2020-2025)
3.3 Global Liposomes Drug Delivery Sale Price by Company
3.4 Key Manufacturers Liposomes Drug Delivery Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liposomes Drug Delivery Product Location Distribution
3.4.2 Players Liposomes Drug Delivery Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Liposomes Drug Delivery by Geographic Region
4.1 World Historic Liposomes Drug Delivery Market Size by Geographic Region (2020-2025)
4.1.1 Global Liposomes Drug Delivery Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Liposomes Drug Delivery Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Liposomes Drug Delivery Market Size by Country/Region (2020-2025)
4.2.1 Global Liposomes Drug Delivery Annual Sales by Country/Region (2020-2025)
4.2.2 Global Liposomes Drug Delivery Annual Revenue by Country/Region (2020-2025)
4.3 Americas Liposomes Drug Delivery Sales Growth
4.4 APAC Liposomes Drug Delivery Sales Growth
4.5 Europe Liposomes Drug Delivery Sales Growth
4.6 Middle East & Africa Liposomes Drug Delivery Sales Growth
5 Americas
5.1 Americas Liposomes Drug Delivery Sales by Country
5.1.1 Americas Liposomes Drug Delivery Sales by Country (2020-2025)
5.1.2 Americas Liposomes Drug Delivery Revenue by Country (2020-2025)
5.2 Americas Liposomes Drug Delivery Sales by Type (2020-2025)
5.3 Americas Liposomes Drug Delivery Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposomes Drug Delivery Sales by Region
6.1.1 APAC Liposomes Drug Delivery Sales by Region (2020-2025)
6.1.2 APAC Liposomes Drug Delivery Revenue by Region (2020-2025)
6.2 APAC Liposomes Drug Delivery Sales by Type (2020-2025)
6.3 APAC Liposomes Drug Delivery Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Liposomes Drug Delivery by Country
7.1.1 Europe Liposomes Drug Delivery Sales by Country (2020-2025)
7.1.2 Europe Liposomes Drug Delivery Revenue by Country (2020-2025)
7.2 Europe Liposomes Drug Delivery Sales by Type (2020-2025)
7.3 Europe Liposomes Drug Delivery Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposomes Drug Delivery by Country
8.1.1 Middle East & Africa Liposomes Drug Delivery Sales by Country (2020-2025)
8.1.2 Middle East & Africa Liposomes Drug Delivery Revenue by Country (2020-2025)
8.2 Middle East & Africa Liposomes Drug Delivery Sales by Type (2020-2025)
8.3 Middle East & Africa Liposomes Drug Delivery Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liposomes Drug Delivery
10.3 Manufacturing Process Analysis of Liposomes Drug Delivery
10.4 Industry Chain Structure of Liposomes Drug Delivery
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liposomes Drug Delivery Distributors
11.3 Liposomes Drug Delivery Customer
12 World Forecast Review for Liposomes Drug Delivery by Geographic Region
12.1 Global Liposomes Drug Delivery Market Size Forecast by Region
12.1.1 Global Liposomes Drug Delivery Forecast by Region (2026-2031)
12.1.2 Global Liposomes Drug Delivery Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Liposomes Drug Delivery Forecast by Type (2026-2031)
12.7 Global Liposomes Drug Delivery Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Johnson & Johnson
13.1.1 Johnson & Johnson Company Information
13.1.2 Johnson & Johnson Liposomes Drug Delivery Product Portfolios and Specifications
13.1.3 Johnson & Johnson Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Johnson & Johnson Main Business Overview
13.1.5 Johnson & Johnson Latest Developments
13.2 Gilead Sciences
13.2.1 Gilead Sciences Company Information
13.2.2 Gilead Sciences Liposomes Drug Delivery Product Portfolios and Specifications
13.2.3 Gilead Sciences Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Gilead Sciences Main Business Overview
13.2.5 Gilead Sciences Latest Developments
13.3 Pacira
13.3.1 Pacira Company Information
13.3.2 Pacira Liposomes Drug Delivery Product Portfolios and Specifications
13.3.3 Pacira Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Pacira Main Business Overview
13.3.5 Pacira Latest Developments
13.4 Sun Pharmaceutical
13.4.1 Sun Pharmaceutical Company Information
13.4.2 Sun Pharmaceutical Liposomes Drug Delivery Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sun Pharmaceutical Main Business Overview
13.4.5 Sun Pharmaceutical Latest Developments
13.5 Luye Pharma
13.5.1 Luye Pharma Company Information
13.5.2 Luye Pharma Liposomes Drug Delivery Product Portfolios and Specifications
13.5.3 Luye Pharma Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Luye Pharma Main Business Overview
13.5.5 Luye Pharma Latest Developments
13.6 Sigma-Tau Group
13.6.1 Sigma-Tau Group Company Information
13.6.2 Sigma-Tau Group Liposomes Drug Delivery Product Portfolios and Specifications
13.6.3 Sigma-Tau Group Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sigma-Tau Group Main Business Overview
13.6.5 Sigma-Tau Group Latest Developments
13.7 Fudan-Zhangjiang
13.7.1 Fudan-Zhangjiang Company Information
13.7.2 Fudan-Zhangjiang Liposomes Drug Delivery Product Portfolios and Specifications
13.7.3 Fudan-Zhangjiang Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Fudan-Zhangjiang Main Business Overview
13.7.5 Fudan-Zhangjiang Latest Developments
13.8 Teva Pharmaceutical
13.8.1 Teva Pharmaceutical Company Information
13.8.2 Teva Pharmaceutical Liposomes Drug Delivery Product Portfolios and Specifications
13.8.3 Teva Pharmaceutical Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Teva Pharmaceutical Main Business Overview
13.8.5 Teva Pharmaceutical Latest Developments
13.9 CSPC
13.9.1 CSPC Company Information
13.9.2 CSPC Liposomes Drug Delivery Product Portfolios and Specifications
13.9.3 CSPC Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 CSPC Main Business Overview
13.9.5 CSPC Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Liposomes Drug Delivery Product Portfolios and Specifications
13.10.3 Novartis Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Kingond Pharm
13.11.1 Kingond Pharm Company Information
13.11.2 Kingond Pharm Liposomes Drug Delivery Product Portfolios and Specifications
13.11.3 Kingond Pharm Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Kingond Pharm Main Business Overview
13.11.5 Kingond Pharm Latest Developments
13.12 Spectrum Pharmaceuticals
13.12.1 Spectrum Pharmaceuticals Company Information
13.12.2 Spectrum Pharmaceuticals Liposomes Drug Delivery Product Portfolios and Specifications
13.12.3 Spectrum Pharmaceuticals Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Spectrum Pharmaceuticals Main Business Overview
13.12.5 Spectrum Pharmaceuticals Latest Developments
13.13 Shanghai New Asia
13.13.1 Shanghai New Asia Company Information
13.13.2 Shanghai New Asia Liposomes Drug Delivery Product Portfolios and Specifications
13.13.3 Shanghai New Asia Liposomes Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Shanghai New Asia Main Business Overview
13.13.5 Shanghai New Asia Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂